Article Text

PDF
N02 Safety And Tolerability Of Selisistat For The Treatment Of Huntington’s Disease: Results From A Randomised, Double-blind, Placebo-controlled Phase Ii Trial
  1. R Reilmann1,
  2. F Squitieri2,
  3. J Priller3,
  4. C Saft4,
  5. C Mariotti5,
  6. SD Süssmuth6,
  7. AH Nemeth7,
  8. SJ Tabrizi8,
  9. O Quarrell9,
  10. D Craufurd10,
  11. H Rickards11,
  12. A Rosser12,
  13. B Darpo13,
  14. M Tessari14,
  15. A Szynol15,
  16. DF Fischer15,
  17. C Frost16,
  18. RE Farmer16,
  19. GB Landwehrmeyer6,
  20. G Westerberg17
  1. 1George-Huntington-Institute and Department of Neurology, University of Muenster, Johann-Krane Weg 27, Muenster, Germany
  2. 2IRCCS Neuromed, 86077 Pozzilli, Italy
  3. 3Charité, Department of Neuropsychiatry, Charitéplatz 1, 10117 Berlin, Germany
  4. 4Ruhruniversity Bochum, Department of Neurology, St. Josef Hospital,Gudrunstraße 56, 44791 Bochum, Germany
  5. 5Fondazione IRCCS Istituto Neruologico Carlo Besta, via Celoria 11, 20133 Milano, Italy
  6. 6University of Ulm, Oberer Eselsberg 45/1, 89081 Ulm, Germany
  7. 7Oxford Radcliffe Hospitals NHS Trust, Department of Clinical Genetics, Old Road, OX3 7LJ Oxford, UK
  8. 8National Hospital for Neurology and Neurosurgery, Department for Neurology, Queen Square, WC1N 3BG London, UK
  9. 9Sheffield Children’s Hospital, Department of Clinical Genetics, Western Bank, S10 2TH Sheffield, UK
  10. 10University of Manchester, Genetic Medicine, St. Mary’s Hospital, Oxford Road, M13 9WL Manchester, UK
  11. 11The Barberry National Centre for Mental Health, Department of Neuropsychiatry, 25 Vincent Drive, Edgbaston, B15 2FG Birmingham, UK
  12. 12Cardiff University, Department of Neurology, Museum Avenue, CF10 3US Cardiff, UK
  13. 13FESC, Trasthagen 11, SE-181 41 Lidingö, Sweden
  14. 14Galapagos B.V., Leiden, The Netherlands
  15. 15BioFocus, a Charles River Company, Leiden, The Netherlands
  16. 16London School of Hygiene and Tropical Medicine, Medical Statistics Unit, WC1E 7HT London, UK
  17. 17Siena Biotech S.p. A., Strada Del Petriccio E Belriguardo, 35, 53100 Siena, Italy

Abstract

Background Selisistat is a first-in-class SirT1 inhibitor shown to be safe and well tolerated in healthy volunteers and HD patients in short-term studies.

Objective To evaluate safety and tolerability of selisistat over 12 weeks in patients with Huntington’s disease (HD).

Design/methods This was a double-blind, placebo-controlled, international multi-centre study of selisistat in individuals with Stage I-III HD. Participants (30–70 yrs) with genetically confirmed HD, a Unified Huntington Disease Rating Scale (UHDRS) Total Motor Score of ≥ 5 and a Total Functional Capacity ≥ 5 were randomised (1:1:1) to selisistat 50 or 200 mg or placebo once daily for 12 weeks. Safety and tolerability were evaluated by monitoring adverse events, vital signs, ECG and laboratory safety data throughout the study. Blood sampling for pharmacokinetics and soluble mutant huntingtin levels were collected throughout.

Results/outcome A total of 144 patients were randomised and 125 patients (87%) completed the study. There were 9 serious adverse events, three in each treatment group, including one death in the placebo group. The most common adverse events were reversible increases in liver function tests without accompanying increases in bilirubin. All of these occurred in the selisistat groups; while most of these increases were <3×ULN, three events were classified as serious. No clinically relevant changes in the UHDRS readouts were observed during the relatively short treatment period. Levels of soluble mutant huntingtin in peripheral blood mononuclear cells showed borderline statistically significant (p = 0.058, p = 0.075) increases of similar magnitude at 12 weeks compared to placebo in the 50mg and 200mg groups respectively, that reverted to levels consistent with the placebo group at follow-up.

Conclusions Apart from increases in liver function tests in a subset of patients, selisistat was safe and well tolerated, and a trend for modulation of the levels of soluble mutant huntingtin was observed.

Acknowledgement Supported by Siena Biotech SpA.

KeyWords
  • huntingtin
  • clinical trial
  • phase II

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.